Summary
Acyloxyalkyl ester prodrugs of histone deacetylase inhibitors, a family of anti-cancer agents, are metabolized intracellularly to acids and aldehyde(s). The purpose of this study was to assess the in vitro and in vivo anticancer activity, selectivity and oral bioavailability of these prodrugs. The prodrugs exhibited a hierarchal potency of AN-193 ≥ AN-7 > AN-1 and AN-9 ≫ AN-10 against murine lung carcinoma (3LLD122) and human breast carcinoma (MCF-7) cell lines. AN-9, and to even greater extent AN-7, displayed preferential cytotoxicity against leukemic and glioblastoma cells compared to their normal cellular counterparts-normal mononuclear and astrocytes cells, respectively. In vivo, anti-metastatic activity was evaluated in a metastatic model of lung cancer in which Lewis lung carcinoma (3LLD122) cells are injected intravenously into C57/BL mice and produce lung nodules. The prodrugs administered orally demonstrated a significant inhibition of lung-lesion formation and their hierarchal potency concurred with that observed in vitro, with the exception of AN-193 that was the least active compound. Escalating doses of AN-7 (5–100 mg/kg), administered by oral or intraperitoneal routes and displayed equivalent anti-metastatic activities, confirmed the good oral bioavailability of AN-7. Consistent with these findings, a time course study of histone acetylation in subcutaneously implanted 3LL122 tumors showed 2–4 fold increases in histone acetylation within 0.5 h of intravenous, intraperitoneal, or oral administration of AN-7 (100 mg/kg). Relative contributions of the prodrug metabolites to the anti-neoplastic activity and the best candidate for clinical studies are discussed.
Similar content being viewed by others
Abbreviations
- BA:
-
butyric acid
- MG:
-
malignant glioma
- DAB:
-
diaminobenzidine
- DMSO:
-
dimethyl sulfoxide
- HDAC:
-
histone deacetylase
- HDACI:
-
histone deacetylase inhibitors
- IHC:
-
immunohistochemistry
- SAR:
-
structure activity relationships
References
Ashton RW, Jett JR (2005) Screening for non-small cells lung cancer. Semin Oncol 32:253–258
Rephaeli A, Shaklai M, Ruse M, Nudelman A (1991) Derivatives of butyric acid as potential anti-neoplastic agents. Int J Cancer 49:66–72
Rabizadeh E, Shaklai M, Nudelman A (1993) Eisenbach L, Rephaeli A: Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBES Lett 328:225–229
Aviram A, Zimrah Y, Shaklai M, Nudelman A, Rephaeli A (1994) Comparison between the effect of butyric acid and its prodrug pivaloyloxymethyl butyrate on histones hyperacetylation in an HL-60 leukemic cell line. Int J Cancer 56:906–909
Zimra Y, Nudelman A, Zhuk R, Rabizadeh E, Shaklai M, Aviram A, Rephaeli A (2000) Uptake of acyloxyalkyl ester prodrugs of butyric acid into leukemic cells and their intracellular esterase-catalyzed hydrolysis. J Cancer Res Clin Oncol 123:152–160
Siu LL, Von Hoff DD, Rephaeli A, Izbicka E, Cerna C, Gomez L, Rowinsky EK, Eckhardt SG (1998) Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Invest New Drugs 16:113–119
Batova A, Shao LE, Diccianni MB, Yu AL, Tanaka T, Rephaeli A, Nudelman A, Yu J (2002) The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 100:3319–3324
Kasukabe T, Rephaeli A, Honma Y (1997) An anti-cancer derivative of butyric acid (pivaloyloxymethyl-butyrate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukemia cells. Br J Cancer 75:850–854
Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone F, Eckhardt GS (2002) A Phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res 8:2142–2148
Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A (2004) Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45:381–386
Nudelman A, Levovich I, Cutts SM, Phillips DR, Rephaeli A (2005) The role of intracellularly released formaldehyde and butyric acid, in the anticancer activity of acyloxyalkyl esters. J Med Chem 48:1042–1054
Nudelman A, Gnizi E, Katz Y, Azulai R, Cohen-Ohana M, Zhuk R, Sampson SR, Langzam L, Fibach E, Prus E, Pugach V, Rephaeli A (2001) Prodrugs of butyric acid (III). Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med Chem 36:63–74
Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z, Nudelman A(2005) In vivo and in vitro anti tumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, on human prostate cancer. Int J Cancer 116:226–235
Yamit-Hezi A, Plaksin D, Eisenbach L (1994) c-fos and c-jun overexpression in malignant cells reduces their tumorigenic and metastatic potential, and affects their MHC class I gene expression. Oncogene 9:1065–1079
Entin-Meer M, Rephaeli A, Yang X, Nudelman A, VandenBerg SR, Haas-Kogan DA: Butyric acid prodrugs are histone deacetylase inhibitors that demonstrate anti neoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol Canc Ther (in press)
McCaffrey TA, Agarwal LA, Weksler BB (1988) A rapid fluorometric DNA assay for the measurement of cell density and proliferation in vitro. Cell Dev Biol 24:247–252
Coradini D, Pellizzaro C, Abolafio G, Bosco M, Scarlata I, Cantoni S, Stucchi L, Zorzet S, Turrin C, Sava G, Perbellini A, Daidone MG (2004) Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study. Invest New Drugs 22:207–217
Rosato RR, Grant S (2003) Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2:30–37
Kelly WK, O’Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923–3931
Nemunaitis JJ, Orr D, Eager R, Cunningham CC, Williams A, Mennel R, Grove W, Olson S (2003) Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J 9:58–66
Cinti DL, Keyes SR, Lemelin MA, Denk H, Schenkman JB (1976) Biochemical properties of rat liver mitochondrial aldehyde dehydrogenase with respect to oxidation of formaldehyde. J Biol Chem 251:1571–1577
Lachner M, Jenuwein T (2002) The many faces of histone lysine methylation. Current Opinion Cell Biol 14:286–298
Kalasz H (2003) Biological role of formaldehyde, and cycles related to methylation, demethylation, and formaldehyde production. Mini Rev Med Chem 3:175–192
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rephaeli, A., Entin-Meer, M., Angel, D. et al. The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs. Invest New Drugs 24, 383–392 (2006). https://doi.org/10.1007/s10637-006-6213-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-006-6213-1